Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Molecular diagnostics company Asuragen has announced the CE-mark and European launch of RNARetain Pre-Analytical RNA Stabilization Solution, the company's clinically validated and RNA stabilization solution.
Subscribe to our email newsletter
Based upon patented technology, RNARetain is labeled for the collection, storage, and transport of clinical human cellular and solid tissue specimens and stabilization of intracellular RNA within these specimens for subsequent extraction and molecular analysis.
According to the company, RNARetain infiltrates tissues and cells, precipitating nucleic acids and proteins in situ providing powerful protection of cellular RNA from both intracellular and extracellular ribonucleases, which would otherwise rapidly degrade the RNA in the specimen.
Matt Winkler, chief scientific officer and CEO of Asuragen, said: “RNARetain will become a valuable tool in molecular diagnostics and future personalized medicine applications by allowing shipment of fresh tumor biopsies at ambient temperature, thus greatly facilitating the logistical process of sample handling.”